Claims for Patent: 8,581,043
✉ Email this page to a colleague
Summary for Patent: 8,581,043
Title: | Nicotiana nucleic acid molecules and uses thereof |
Abstract: | The present invention features Nicotiana nucleic acid sequences such as sequences encoding constitutive, or ethylene or senescence induced polypeptides, in particular cytochrome p450 enzymes, in Nicotiana plants and methods for using these nucleic acid sequences and plants to alter desirable traits, for example by using breeding protocols. |
Inventor(s): | Xui; Dongmei (Glen Allen, VA), Nielsen; Mark T. (Nicholas, KY) |
Assignee: | U.S. Smokeless Tobacco Company LLC (Richmond, VA) |
Application Number: | 12/755,733 |
Patent Claims: | 1. A method for reducing the expression of nicotine demethylase in a tobacco plant, said method comprising expressing a transgene encoding an antisense RNA molecule that
inhibits expression of said nicotine demethylase in said plant, said antisense RNA molecule comprising at least 25 consecutive nucleotides that have 100% sequence identity to an intron of SEQ ID NO: 4, wherein expression of said nicotine demethylase is
inhibited in said plant relative to a tobacco plant lacking said transgene.
2. The method of claim 1, wherein said tobacco plant is from a species selected from the group consisting of Nicotiana tabacum, Nicotiana sylvestris, Nicotiana tomentosiformis, and Nicotiana glauca. 3. The method of claim 1, wherein said transgene comprises a constitutive promoter. 4. The method of claim 1, wherein said transgene comprises an inducible promoter. 5. The method of claim 1, wherein said antisense RNA molecule comprises at least 100 nucleotides that have 100% sequence identity to an intron of SEQ ID NO: 4. 6. The method of claim 1, wherein said antisense RNA molecule comprises at least 250 nucleotides that have 100% sequence identity to an intron of SEQ ID NO: 4. 7. The method of claim 1, wherein said antisense RNA molecule comprises at least 500 nucleotides that have 100% or greater sequence identity to an intron of SEQ ID NO: 4. 8. The method of claim 1, wherein said tobacco plant is Nicotiana tabacum. |
Details for Patent 8,581,043
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2021-11-13 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2021-11-13 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2021-11-13 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.